**General description**

<table>
<thead>
<tr>
<th><strong>INN</strong></th>
<th>Piperacillin + tazobactam</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ATC codes</strong></td>
<td>J01CR05</td>
</tr>
<tr>
<td><strong>Medicine type</strong></td>
<td>Chemical agent</td>
</tr>
<tr>
<td><strong>Antibiotic groups</strong></td>
<td><a href="#">WATCH</a></td>
</tr>
</tbody>
</table>
| **EML status history** | First added in 2017 (TRS 1006) for Neutropenia  
Added in 2017 (TRS 1006) for Peritoneal abscess  
Added in 2017 (TRS 1006) for Peritonitis  
Added in 2017 (TRS 1006) for Other specified pneumonia  
Added in 2021 (TRS 1035) for Necrotising fasciitis |
| **Wikipedia**       | [Piperacillin + tazobactam](#) |
| **DrugBank**        | [Piperacillin](#), [Tazobactam](#) |

**Recommendations**

**Section**  | **Watch group antibiotics**
---|---
Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

**Indications**

**First choice**
- Peritoneal abscess (severe)
- Peritonitis (severe)
- Neutropenia (high-risk)
- Other specified pneumonia (Hospital-acquired pneumonia)
Access group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice
co-prescribed with clindamycin

Necrotising fasciitis